Alkermes to submit schizophrenia med this year

Share this article:

Dublin's Alkermes plc is gearing up to file its experimental schizophrenia medication with the FDA by the third quarter of this year. The company said in a statement Tuesday that Phase-III results, which demonstrated the impact of the monthly injection, are behind its submission plans.

Three patient cohorts were studied: one which received 441 mg of aripiprazole lauroxil, another given 882 mg of the same drug, and a third that served as the control group. The extended-release drug converts the medication into aripiprazole, also known as Abilify.

Data showed “statistically significant reductions from baseline in Positive and Negative Syndrome Scale,” at 12 weeks.

Tuesday's news follows last month's J&J announcement that it, too, was going to file a long-acting schizophrenia medication with the FDA. J&J said it expects to submit its request for the drug, intended to be dosed four times a year, by the end of 2014.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.